MedTrace Logo

Tarceva With or Without Apatinib in the Advanced Lung Adenocarcinoma

NCT02704767 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2016-03-10

No results posted yet for this study

Summary

Tarceva now was established first-line therapy for advanced lung adenocarcinoma with mutant EGFR patients.However,the benefit lasted for about 6-8 months.So we consider to add apatinib,a tyrosine kinase inhibitor of VEGF,to the therapy of these patients.

Conditions

Interventions

DRUG

Apatinib

a tyrosine kinase inhibitor of VEGF invented by Hengrui pharma in China

DRUG

Tarceva

DRUG

Placebo

Sponsors & Collaborators

  • First Affiliated Hospital of Kunming Medical University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-06-30
Primary Completion
2019-06-30
Completion
2019-12-31

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02704767 on ClinicalTrials.gov